Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Dabigatran etexilate is a prescription oral anticoagulant and direct thrombin inhibitor. It is used in adults to reduce stroke and systemic embolism risk with nonvalvular atrial fibrillation, treat deep vein thrombosis or pulmonary embolism after initial parenteral anticoagulation, reduce recurrent venous clots, and prevent clots after hip replacement surgery.
read more about dabigatran ...Dabigatran and its active metabolites directly inhibit thrombin. Thrombin normally converts fibrinogen into fibrin during the clotting cascade and also activates platelets. Blocking free and clot-bound thrombin reduces fibrin formation and thrombin-induced platelet aggregation, lowering the body's ability to form or extend blood clots.
Adult indications include nonvalvular atrial fibrillation, treatment of deep vein thrombosis and pulmonary embolism after five to ten days of parenteral anticoagulation, prevention of recurrent deep vein thrombosis or pulmonary embolism, and clot prevention after hip replacement. Capsules also treat and reduce recurrent venous thromboembolism in patients age 8 to under 18 under weight-based dosing.
Adults with nonvalvular atrial fibrillation and creatinine clearance above 30 mL per minute commonly take 150 mg twice daily. Adult deep vein thrombosis or pulmonary embolism treatment also uses 150 mg twice daily after five to ten days of parenteral anticoagulation. Hip replacement prophylaxis starts with 110 mg on the first day, then 220 mg once daily.
Dabigatran carries boxed warnings for increased thrombotic risk after premature discontinuation and spinal or epidural hematoma during neuraxial procedures. Bleeding can be serious or fatal. Active pathological bleeding, serious hypersensitivity, and mechanical prosthetic heart valves are contraindications. Kidney function and interacting P-glycoprotein medicines influence dosing and safety.
Yes. Dabigatran is an oral anticoagulant that directly inhibits thrombin.
Adults with creatinine clearance above 30 mL per minute commonly take 150 mg twice daily.
No. Dabigatran is contraindicated in patients with mechanical prosthetic heart valves.
Yes. The boxed warnings cover thrombotic events after premature discontinuation and spinal or epidural hematoma.
Dabigatran. MedlinePlus. https://medlineplus.gov/druginfo/meds/a610024.html. Date Accessed September 24, 2026.
Dabigatran. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Dabigatran. Date Accessed September 24, 2026.
DailyMed - DABIGATRAN ETEXILATE capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=834a3c5f-b723-4bcb-a560-dc305dd0d829. Date Accessed September 24, 2026.
DailyMed - PRADAXA (dabigatran etexilate mesylate) capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9. Date Accessed September 24, 2026.
FDA Label - PRADAXA (dabigatran etexilate) Capsules. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022512s049lbl.pdf. Date Accessed September 24, 2026.